Studies on some coagulation factors (Hageman factor, plasma prekallikrein, and high molecular weight kininogen) in the normal newborn. 1980

E M Gordon, and O D Ratnoff, and H Saito, and S Gross, and P K Jones

Normal newborn infants have a prolonged partial thromboplastin time compared to that of older infants or adults. This finding has been related to combined deficiencies of multiple clotting factors, with the exception of proaccelerin (factor V) and antihemophilic factor (factor VIII). The present study confirms the presence of decreased titers of Hageman factor (HF, factor XII), plasma prekallikrein, and high molecular weight kininogen during the neonatal period, as demonstrated in clotting assays; the degree of these relative deficiencies is usually such that only the low titer of HF appears to contribute significantly to the abnormally long PTT. Additionally, procoagulant titers of HF and plasma prekallikrein were relatively lower than the concentration of these factors determined immunologically. The mechanisms underlying this phenomenon are not known.

UI MeSH Term Description Entries
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D007704 Kininogens Endogenous peptides present in most body fluids. Certain enzymes convert them to active KININS which are involved in inflammation, blood clotting, complement reactions, etc. Kininogens belong to the cystatin superfamily. They are cysteine proteinase inhibitors. HIGH-MOLECULAR-WEIGHT KININOGEN; (HMWK); is split by plasma kallikrein to produce BRADYKININ. LOW-MOLECULAR-WEIGHT KININOGEN; (LMWK); is split by tissue kallikrein to produce KALLIDIN. Cystatins, Kininogen,Kininogen,Prekinins,Prokinins,T-Kininogen,Thiostatin,Kininogen Cystatins,T Kininogen
D008970 Molecular Weight The sum of the weight of all the atoms in a molecule. Molecular Weights,Weight, Molecular,Weights, Molecular
D010314 Partial Thromboplastin Time The time required for the appearance of FIBRIN strands following the mixing of PLASMA with phospholipid platelet substitute (e.g., crude cephalins, soybean phosphatides). It is a test of the intrinsic pathway (factors VIII, IX, XI, and XII) and the common pathway (fibrinogen, prothrombin, factors V and X) of BLOOD COAGULATION. It is used as a screening test and to monitor HEPARIN therapy. Activated Partial Thromboplastin Time,Cephalin-Kaolin Coagulation Time,Kaolin-Cephalin Coagulation Time,Thromboplastin Time, Partial,Coagulation Time, Cephalin-Kaolin,Cephalin Kaolin Coagulation Time,Coagulation Time, Cephalin Kaolin,Coagulation Time, Kaolin-Cephalin,Kaolin Cephalin Coagulation Time
D011288 Prekallikrein A plasma protein which is the precursor of kallikrein. Plasma that is deficient in prekallikrein has been found to be abnormal in thromboplastin formation, kinin generation, evolution of a permeability globulin, and plasmin formation. The absence of prekallikrein in plasma leads to Fletcher factor deficiency, a congenital disease. Fletcher Factor,Plasma Prokallikrein,Kallikreinogen,Plasma Prokallikrein A,Factor, Fletcher,Prokallikrein A, Plasma,Prokallikrein, Plasma
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D001779 Blood Coagulation Factors Endogenous substances, usually proteins, that are involved in the blood coagulation process. Clotting Factor,Coagulation Factors,Blood Coagulation Factor,Clotting Factors,Coagulation Factor,Coagulation Factor, Blood,Coagulation Factors, Blood,Factor, Coagulation,Factors, Coagulation,Factor, Blood Coagulation,Factor, Clotting,Factors, Blood Coagulation,Factors, Clotting
D005174 Factor XII Stable blood coagulation factor activated by contact with the subendothelial surface of an injured vessel. Along with prekallikrein, it serves as the contact factor that initiates the intrinsic pathway of blood coagulation. Kallikrein activates factor XII to XIIa. Deficiency of factor XII, also called the Hageman trait, leads to increased incidence of thromboembolic disease. Mutations in the gene for factor XII that appear to increase factor XII amidolytic activity are associated with HEREDITARY ANGIOEDEMA TYPE III. Coagulation Factor XII,Hageman Factor,Factor 12,Factor Twelve
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000941 Antigens Substances that are recognized by the immune system and induce an immune reaction. Antigen

Related Publications

E M Gordon, and O D Ratnoff, and H Saito, and S Gross, and P K Jones
January 1987, Seminars in thrombosis and hemostasis,
E M Gordon, and O D Ratnoff, and H Saito, and S Gross, and P K Jones
February 1979, Proceedings of the National Academy of Sciences of the United States of America,
E M Gordon, and O D Ratnoff, and H Saito, and S Gross, and P K Jones
November 1976, Thrombosis research,
E M Gordon, and O D Ratnoff, and H Saito, and S Gross, and P K Jones
September 1986, Journal of clinical pathology,
E M Gordon, and O D Ratnoff, and H Saito, and S Gross, and P K Jones
May 1980, Biochemical pharmacology,
E M Gordon, and O D Ratnoff, and H Saito, and S Gross, and P K Jones
July 1977, The Journal of clinical investigation,
E M Gordon, and O D Ratnoff, and H Saito, and S Gross, and P K Jones
January 1979, Transactions of the Association of American Physicians,
E M Gordon, and O D Ratnoff, and H Saito, and S Gross, and P K Jones
January 1977, The Journal of laboratory and clinical medicine,
E M Gordon, and O D Ratnoff, and H Saito, and S Gross, and P K Jones
January 1978, Progress in hemostasis and thrombosis,
Copied contents to your clipboard!